Experimental Tinnitus Treatment With Transcranial Magnetic Stimulation
Primary Purpose
Tinnitus
Status
Terminated
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
TMS for tinnitus
Sponsored by
About this trial
This is an interventional treatment trial for Tinnitus focused on measuring transcranial magnetic stimulation, neuromodulation
Eligibility Criteria
Inclusion Criteria:
- tinnitus diagnosis
Exclusion Criteria:
- have epilepsy or a family history of epilepsy
- have implanted metal in or near their head
- have any history of brain injury or stroke
- have a tinnitus handicap inventory score of <38 (less than moderate handicap)
Sites / Locations
- University of Iowa
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Active TMS
Arm Description
Active TMS stimulation administered for tinnitus symptoms (no sham stimulation).
Outcomes
Primary Outcome Measures
Clinical Improvement
Clinical Global Improvement Scale (0-7 scale where 0=not assessed, 1=Very much improved, and 7= Very much worse
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03699826
Brief Title
Experimental Tinnitus Treatment With Transcranial Magnetic Stimulation
Official Title
Experimental Tinnitus Treatment With Transcranial Magnetic Stimulation
Study Type
Interventional
2. Study Status
Record Verification Date
June 2023
Overall Recruitment Status
Terminated
Why Stopped
No funding source
Study Start Date
December 10, 2018 (Actual)
Primary Completion Date
July 26, 2021 (Actual)
Study Completion Date
July 26, 2021 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Aaron Boes
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
There are numerous conditions that may benefit from TMS but they lack definitive data from clinical trials with sufficient scientific rigor, which includes large, multi-site, randomized sham-controlled trials. This is the status for a variety of psychiatric and neurological disorders such as tinnitus, central pain, movement disorders, stroke rehabilitation, obsessive compulsive disorders, anxiety, schizophrenia, and addiction. In certain instances there may be sufficient evidence supporting the treatment efficacy of TMS that it is reasonable to offer TMS as an off-label treatment, a term for clinical treatments that have not received FDA approval but may nonetheless be helpful for patients. In other cases there is such a paucity of clinical trial data that the use of therapeutic TMS is less appropriate as a clinical treatment that the patient is charged for out of pocket and may cost several thousand dollars, but is better suited for clinically-oriented research. This has the added benefit of potentially helping the patient and providing investigators with additional information from which to inform future clinical trials. In this study the investigators propose to use TMS to treat tinnitus, for which few other treatments currently exist. Tinnitus affects approximately 1% of the population and can be debilitating for patients. Recent studies have shown some promise in reducing symptoms through neuromodulation, but results are variable and more research is needed to improve treatment protocols. The investigators plan to contribute to this body of research by taking an evidence-based approach to test whether TMS is effective at reducing symptoms of tinnitus. Each subject's MRI will be used to perform neuronavigated TMS stimulations while documenting changes in symptom severity with self-report questionnaires and symptom severity scales. If it is determined that a stimulation protocol is effective, 1-2 weeks of daily treatments will be scheduled as part of that subject's personalized treatment plan.
Detailed Description
Consent patients that have been referred to the Noninvasive Brain Stimulation Clinic at the University of Iowa.
Patients will complete the following before any treatments occur: Tinnitus Intake Questionnaire, Tinnitus Functional Index, Tinnitus Questionnaires, Iowa Tinnitus Primary Function, Clinical Global Improvement Scale.
Patients may undergo audiological assessment if they have not already been tested prior to the study.
Patients will be required to obtain an MRI prior to treatment to aid in neuronavigated stimulation unless there is have access to a previous clinical MRI for this purpose.
MRI images will be loaded into BrainSight or Localite, which are both frameless stereotactic systems for MRI-guided TMS localization. If no MRI is acquired, the subject's head will be transformed to MNI standard space within the software. Neuronavigation allows us to place specific stimulation targets onto each subjects's MRI. For this study, the investigators will be targeting left dorsolateral prefrontal cortex, auditory cortices, and auditory association cortices; all targets are placed anatomically by a neurologist. Infrared trackers on the subject's head and TMS coil allow for neuronavigated stimulation of anatomical targets on the cortex with millimeter precision.
The motor threshold of the subject will be assessed, which is the intensity of TMS required to elicit motor evoked potentials from the hand 50% of the time.
Subjects will be fitted with an EEG cap to record neural activity before, during, and after the initial test session.
Single TMS pulses or brief trains of repetitive TMS lasting a few seconds will be administered at 80 - 120% of motor threshold to targeted regions of the cerebral cortex and cerebellum. A typical experiment will last 30 minutes to 2 hours. The patients are told they can stop the experiment at any time.
After each stimulation, patients will be asked to rate any changes in symptom severity and whether any side effects were experienced (Tinnitus Questionnaires, Clinical Global Improvement Scale).
After the treatment session, the TMS pulse locations will be related to changes in symptom severity as measured by self-report. If any stimulation treatments were successful in reducing symptom severity, a treatment plan for that target will be discussed and follow-up treatments may be scheduled.
Follow up treatments will vary between patients but will typically consist of daily treatments for up to 4 weeks or until treatment response is sustained. The patient can withdraw from follow treatments at any time. Patients will be asked to complete the following at these visits: Tinnitus Functional Index, Tinnitus Questionnaires, Iowa Tinnitus Primary Function, Clinical Global Improvement Scale.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Tinnitus
Keywords
transcranial magnetic stimulation, neuromodulation
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
1 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Active TMS
Arm Type
Experimental
Arm Description
Active TMS stimulation administered for tinnitus symptoms (no sham stimulation).
Intervention Type
Device
Intervention Name(s)
TMS for tinnitus
Intervention Description
Targeted stimulation to decrease tinnitus symptom severity.
Primary Outcome Measure Information:
Title
Clinical Improvement
Description
Clinical Global Improvement Scale (0-7 scale where 0=not assessed, 1=Very much improved, and 7= Very much worse
Time Frame
End of treatment course - 5 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
tinnitus diagnosis
Exclusion Criteria:
have epilepsy or a family history of epilepsy
have implanted metal in or near their head
have any history of brain injury or stroke
have a tinnitus handicap inventory score of <38 (less than moderate handicap)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Aaron D Boes, MD, PhD
Organizational Affiliation
University of Iowa
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Iowa
City
Iowa City
State/Province
Iowa
ZIP/Postal Code
52242
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Experimental Tinnitus Treatment With Transcranial Magnetic Stimulation
We'll reach out to this number within 24 hrs